EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synthetic circRNA therapeutics: innovations, strategies, and future horizons

Jingsheng Cai, Zonghao Qiu, William Chi-Shing Cho, Zheng Liu, Shaoyi Chen, Haoran Li, Kezhong Chen, Yun Li, Chijian Zuo, Mantang Qiu

MedComm · 2024-11 · 5 (11)

DOI: 10.1002/mco2.720 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 09.11.2024. Verfasst von Jingsheng Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer Peking University People's Ho…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative. The success of COVID‐19 vaccines has underscored the transformative potential of mRNA in RNA therapeutics. Within the RNA family, there is another unique type known as circRNA. This single‐stranded closed‐loop RNA molecule offers notable advantages over mRNA, including enhanced stability and prolonged protein expression, which may significantly impact therapeutic strategies. Furthermore, circRNA plays a pivotal role in the pathogenesis of various diseases, such as cancers, autoimmune disorders, and cardiovascular diseases, making it a promising clinical intervention target. Despite these benefits, the application of circRNA in clinical settings remains underexplored. This review provides a comprehensive overview of the current state of synthetic circRNA therapeutics, focusing on its synthesis, optimization, delivery, and diverse applications. It also addresses the challenges impeding the advancement of circRNA therapeutics from bench to bedside. By summarizing these aspects, the review aims to equip researchers with insights into the ongoing developments and future directions in circRNA therapeutics. Highlighting both the progress and the existing gaps in circRNA research, this review offers valuable perspectives for advancing the field and guiding future investigations.

Schlagwörter

Stichwörter der Autor:innen

circRNA vaccinegroup I introninternal ribosome entry sitelipid nanoparticlesynthetic circRNA

Autor:innen und Institutionen

  • Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer Peking University People's Hospital Beijing China.
  • Department of Thoracic Surgery Peking University People's Hospital Beijing China.
  • Institute of Advanced Clinical Medicine Peking University Beijing China.
  • Suzhou CureMed Biopharma Technology Co., Ltd. Suzhou China.
  • Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China.

Förderung

  • National Key Research and Development Program of China
  • Beijing Nova Program

Zitieren

APA

Cai, J., Qiu, Z., Chi-Shing Cho, W., Liu, Z., Chen, S., Li, H., Chen, K., Li, Y., Zuo, C., & Qiu, M. (2024). Synthetic circRNA therapeutics: innovations, strategies, and future horizons. MedComm, 5(11). https://doi.org/10.1002/mco2.720

Vancouver

Cai J, Qiu Z, Chi-Shing Cho W, Liu Z, Chen S, Li H, et al. Synthetic circRNA therapeutics: innovations, strategies, and future horizons. MedComm. 2024;5(11). doi:10.1002/mco2.720

BibTeX
@article{Cai2024,
  author = {Cai, Jingsheng and Qiu, Zonghao and Chi-Shing Cho, William and Liu, Zheng and Chen, Shaoyi and Li, Haoran and Chen, Kezhong and Li, Yun and Zuo, Chijian and Qiu, Mantang},
  title = {Synthetic circRNA therapeutics: innovations, strategies, and future horizons},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {11},
  doi = {10.1002/mco2.720}
}
Kostenlos starten →